Federated Hermes’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-7,521
| Closed | -$283K | – | 2416 |
|
|
2021
Q1 | $283K | Buy |
7,521
+7,490
| +24,161% | +$187K | ﹤0.01% | 1653 |
|
|
2020
Q4 | $1K | Sell |
31
-148
| -83% | -$1.85K | ﹤0.01% | 2220 |
|
|
2020
Q3 | $1K | Hold |
179
| – | – | ﹤0.01% | 2233 |
|
|
2020
Q2 | $1K | Sell |
179
-154
| -46% | -$634 | ﹤0.01% | 2216 |
|
|
2020
Q1 | $1K | Buy |
+333
| New | +$1.41K | ﹤0.01% | 2206 |
|
|
2019
Q3 | – | Sell |
-320
| Closed | -$2K | – | 2329 |
|
|
2019
Q2 | $2K | Sell |
320
-5,851
| -95% | -$55.9K | ﹤0.01% | 2091 |
|
|
2019
Q1 | $82K | Buy |
6,171
+5,893
| +2,120% | +$67.2K | ﹤0.01% | 1614 |
|
|
2018
Q4 | $3K | Buy |
278
+99
| +55% | +$1.18K | ﹤0.01% | 2063 |
|
|
2018
Q3 | $2K | Buy |
+179
| New | +$2.66K | ﹤0.01% | 2168 |
|
|
2017
Q1 | – | Sell |
-23
| Closed | -$1K | – | 2212 |
|
|
2016
Q4 | $1K | Sell |
23
-25,685
| -100% | -$1.35M | ﹤0.01% | 2081 |
|
|
2016
Q3 | $1.35M | Sell |
25,708
-3,773
| -13% | -$180K | ﹤0.01% | 1009 |
|
|
2016
Q2 | $1.22M | Buy |
+29,481
| New | +$1.28M | ﹤0.01% | 1033 |
|
|
2014
Q2 | – | Sell |
-1,818
| Closed | -$36K | – | 2020 |
|
|
2014
Q1 | $36K | Buy |
+1,818
| New | +$30.9K | ﹤0.01% | 1677 |
|
Federated Hermes's FPRX Position: Q2 2021 in Review
Federated Hermes sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 7,521 shares — an estimated $283K sold.
Federated Hermes first reported a position in FPRX in Q1 2014 and held it in 13 quarters. The position peaked at $1.35M in Q3 2016. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- Federated Hermes reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- Federated Hermes sold 7,521 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $283K.
- Federated Hermes first reported a position in Five Prime Therapeutics, Inc. in Q1 2014 and held it in 13 quarters.
- Federated Hermes's Five Prime Therapeutics, Inc. position peaked at $1.35M in Q3 2016.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on Federated Hermes's 13F filing for Q2 2021, filed 16 Aug 2021.